Sonny Valindra
Colossal Biosciences, the ambitious de-extinction startup that first garnered significant attention for its pursuit of resurrecting the woolly mammoth and the dire wolf, is reportedly in advanced discussions to secure new funding at a valuation ranging from $20 billion to $30 billion. This potential capital infusion, as reported by Axios, marks a substantial leap from its previous $10.2 billion valuation achieved in January 2025, underscoring a dramatic acceleration in the company’s perceived market value. The surge in valuation comes at a time when Colossal Biosciences has demonstrably begun to generate revenue, a critical milestone for a company that, until recently, was primarily defined by its groundbreaking, albeit speculative, scientific endeavors.
The company, now approximately five years old, has not disclosed the specific lead investors for this prospective funding round, nor the exact amount of capital it intends to raise. However, the reported valuation suggests a strong investor confidence in Colossal’s long-term vision and its rapidly expanding technological and commercial footprint. This move into revenue generation signifies a pivotal shift from pure research and development to a more sustainable business model, bolstering its appeal to the investment community.
A Diversified Revenue Strategy Beyond De-Extinction
Colossal Biosciences’ co-founder and CEO, Ben Lamm, had previously outlined a multi-pronged revenue strategy, and recent developments indicate the company is actively executing on these fronts. One significant avenue for revenue generation involves the application of its proprietary conservation technologies. Colossal has reportedly offered its expertise and tools to governmental bodies, including a notable collaboration with the U.S. government and a substantial $60 million investment from the United Arab Emirates (UAE). This investment, as highlighted by Wired, signals a recognition of Colossal’s potential to contribute to global conservation efforts, extending its impact beyond the sensational headlines of de-extinction.
Furthermore, Colossal has strategically spun out several subsidiary companies, each targeting distinct market opportunities with applications derived from its core scientific advancements. These ventures serve not only as potential revenue generators but also as testbeds for Colossal’s underlying technologies.
- Breaking: This startup focuses on the critical environmental challenge of plastic degradation, developing innovative solutions to break down persistent plastic waste. The development of such technologies aligns with increasing global demand for sustainable solutions to environmental pollution.
- Form Bio: A computational biology platform, Form Bio has already achieved significant traction, securing $30 million in funding. This platform likely leverages Colossal’s advanced data analysis and modeling capabilities, which are essential for complex genetic engineering and biological research.
- Astromech: This AI-driven predictive modeling company concentrates on biology and life sciences. Its valuation at an impressive $2 billion in March 2026, as reported by D Magazine, underscores the significant market appetite for AI applications in biological research and development, a field where Colossal possesses deep expertise.
These spin-offs demonstrate Colossal’s capacity to translate its foundational research into commercially viable products and services across diverse sectors, thereby de-risking its overall business model and broadening its appeal to investors interested in deep-tech innovation.
Expanding the De-Extinction Portfolio and Conservation Arm
Beyond its commercial ventures, Colossal Biosciences continues to expand its de-extinction portfolio and enhance its conservation initiatives. The company’s headquarters, a 55,000-square-foot facility in Dallas, serves as the hub for its multifaceted operations. In late April 2026, Colossal announced the addition of the bluebuck antelope to its list of target species for de-extinction. This iconic extinct antelope joins a growing roster that includes the woolly mammoth, the dodo bird, and the dire wolf, indicating a broadening ambition within the de-extinction space.
The Colossal Foundation, the company’s nonprofit conservation arm, has also been actively engaged in impactful projects. A recent partnership with the University of Tasmania aims to combat the devastating Devil Facial Tumour Disease (DFTD) affecting Tasmanian devils. Through the application of vaccines and gene-editing technologies, this collaboration highlights Colossal’s commitment to leveraging its scientific prowess for immediate conservation challenges, even as it pursues its more ambitious de-extinction goals. This dual approach—pursuing long-term resurrection projects while contributing to present-day conservation crises—provides a more nuanced narrative for the company’s overall mission and impact.
Revolutionary Reproductive Technologies and Future Revenue Streams
A key technological advancement that Colossal Biosciences is poised to commercialize is its artificial animal womb technology. Co-founder Ben Lamm indicated last year to TechCrunch that the company planned to spin off this technology, recognizing its potential applications beyond animal reproduction, including human fertility treatments. In May 2026, Lamm told Rolling Stone that this groundbreaking technology is anticipated to be ready for deployment within the next year. The prospect of a viable artificial womb could revolutionize reproductive medicine and offers a significant, potentially lucrative, new revenue stream for Colossal, separate from its de-extinction projects.
Looking further ahead, Colossal envisions generating revenue through the sale of biodiversity credits. This market-based mechanism, analogous to carbon credits, would reward successful reintroduction of extinct species into their native habitats. If Colossal can indeed bring back species like the woolly mammoth and the dodo bird and facilitate their integration into ecosystems, the creation of valuable biodiversity credits could represent a substantial future revenue stream, directly linking ecological restoration with financial incentives.
A Booming Deep-Tech Landscape
The timing of Colossal Biosciences’ new fundraising effort is particularly noteworthy, occurring amidst a broader surge in investment across deep-tech sectors. Areas such as longevity technology, alternative energy, and advanced biotechnology are experiencing significant investor interest, creating a favorable environment for companies like Colossal that operate at the forefront of scientific innovation. The increasing recognition of the long-term economic and societal benefits of these advanced technologies is likely fueling investor confidence in Colossal’s ambitious undertakings.
The company’s ability to attract such significant interest and potential investment at a vastly increased valuation, even while still in its relatively early stages of commercialization, speaks to the transformative potential of its scientific breakthroughs. The narrative of bringing back extinct species, while captivating, appears to be increasingly underpinned by tangible technological development and a diversified business strategy that extends far beyond the initial de-extinction concept. Colossal Biosciences is positioning itself not just as a de-extinction company, but as a leader in applied genetic engineering, computational biology, and advanced reproductive technologies, with a clear path towards revenue generation and market leadership.
Colossal Biosciences did not respond to requests for comment regarding the specifics of the reported funding talks. However, the consistent progress in its scientific endeavors, the strategic expansion of its business ventures, and the burgeoning interest from the investment community collectively paint a picture of a company rapidly evolving and solidifying its position as a significant player in the future of biotechnology and conservation. The valuation discussions reflect a growing belief that Colossal’s innovative technologies, born from the audacious goal of de-extinction, have far-reaching applications that can deliver substantial economic and ecological value.
